myelodysplastic syndromes (MDS) | Page 15 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs. de novo myelodysplastic syndromes: A report on behalf of the MDS clinical research consortium

Author(s): 
Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R
Primary Author: 
Zeidan AM
Journal Title: 
Leukemia
Original Publication Date: 
Jan 2017

While therapy-related (t)-MDS has worse outcomes than de novo MDS (d-MDS), some t-MDS patients have an indolent course. Most MDS prognostic models excluded t-MDS patients during development.

Bone Marrow Diseases: 

Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes

Author(s): 
Chou WC, Yeh SP, Hsiao LT, Lin SF, Chen YC, Chen TY, Laille E, Galettis A, Dong Q, Songer S, Beach CL
Primary Author: 
Chou WC
Journal Title: 
Asia Pac J Clin Oncol
Original Publication Date: 
Jan 2017

AIM:

Bone Marrow Diseases: 

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Author(s): 
Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA
Primary Author: 
Greenberg PL
Journal Title: 
J Natl Compr Canc Netw
Original Publication Date: 
Jan 2017

The

Bone Marrow Diseases: 

Impact of Achievement of Complete Cytogenetic Response on Outcome in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents

Author(s): 
Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G
Primary Author: 
Jabbour E
Journal Title: 
Am J Hematol
Original Publication Date: 
Jan 2017

We reviewed 216 consecutive patients with MDS and abnormal karyotype treated with hypomethylating agents between 4/04 and 10/12. Median follow-up was 17 months. Using IWG criteria, best responses were complete response (CR) in 79 patients (37%), partial response (PR) in 4 (2%), and hematologic improvement (HI) in 10 (5%). Cytogenetic response (CyR) was achieved in 78 patients (36%): complete (CCyR) in 62 (29%) and partial in 16 (7%). CyR was achieved in 48 of 79 patients (61%) with CR, 1 of 14 (7%) with PR/HI, and in 29 of the 123 (24%) with no morphologic response.

Bone Marrow Diseases: 

MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia

Author(s): 
Guo Y, Strickland SA, Mohan S, Li S, Bosompem A, Vickers KC, Zhao S, Sheng Q, Kim AS
Primary Author: 
Guo Y
Journal Title: 
Leuk Lymphoma
Original Publication Date: 
Jan 2017

Bone Marrow Diseases: